Bristol-Myers Squibb Co (LTS:0R1F) Additional Paid-In Capital : $45,655 Mil(As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Bristol-Myers Squibb Co Additional Paid-In Capital?

Bristol-Myers Squibb Co's quarterly additional paid-in capital increased from Sep. 2023 ($44,849 Mil) to Dec. 2023 ($45,684 Mil) but then stayed the same from Dec. 2023 ($45,684 Mil) to Mar. 2024 ($45,655 Mil).

Bristol-Myers Squibb Co's annual additional paid-in capital increased from Dec. 2021 ($44,361 Mil) to Dec. 2022 ($45,165 Mil) and increased from Dec. 2022 ($45,165 Mil) to Dec. 2023 ($45,684 Mil).

Bristol-Myers Squibb Co Additional Paid-In Capital Historical Data

The historical data trend for Bristol-Myers Squibb Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Additional Paid-In Capital Chart

Bristol-Myers Squibb Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

43,709.00

44,325.00

44,361.00

45,165.00

45,684.00

Bristol-Myers Squibb Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															45,140.00	45,299.00	44,849.00	45,684.00	45,655.00

Bristol-Myers Squibb Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Bristol-Myers Squibb Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co (LTS:0R1F) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (LTS:0R1F) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Bristol-Myers Squibb Co (LTS:0R1F) Headlines

No Headlines